Are you exploring the Europe COVID-19 Diagnostics Market and looking for actionable insights for investment and strategic planning?

With the continued evolution of the COVID-19 pandemic, government-led testing programs, and the rising demand for rapid and accurate diagnostics, this market has become a critical segment within the European healthcare landscape.

The Europe COVID-19 Diagnostics Market includes molecular, antigen, and antibody tests used to detect SARS-CoV-2 infections. Valued at USD 14.44 Billion in 2025, it is projected to reach USD 17.78 Billion by 2035, growing at a CAGR of 2.10%. The market’s strategic significance lies in enabling public health surveillance, informing treatment decisions, and facilitating pandemic control measures across Europe.

This report provides an in-depth overview for investors, analysts, and business decision-makers seeking to understand current dynamics, emerging opportunities, and long-term market potential.

What Is the Europe COVID-19 Diagnostics Market and Why Is It Important?

The Europe COVID-19 Diagnostics Market encompasses all testing solutions and services for detecting SARS-CoV-2 infections in European countries. Diagnostics solutions are broadly categorized into molecular tests (PCR), antigen tests, antibody tests, and other emerging technologies.

Why it matters:

  1. Public Health Management – Early detection of COVID-19 cases helps prevent outbreaks and informs vaccination strategies.

  2. Clinical Decision Support – Rapid diagnostics enable healthcare providers to identify infected patients and administer appropriate care.

  3. Government Programs – Mass screening, contact tracing, and workplace testing drive demand for diagnostics.

  4. Economic Recovery – Efficient testing facilitates safe reopening of schools, offices, and international travel.

Europe remains a leading region in COVID-19 diagnostics due to strong healthcare infrastructure, regulatory support, and high adoption of point-of-care and laboratory-based testing solutions.

What Is the Current Market Size and Forecast Growth?

  • Base Year (2025): USD 14.44 Billion

  • Forecast Year (2035): USD 17.78 Billion

  • CAGR (2026–2035): 2.10%

Despite the plateauing of COVID-19 cases in some European countries, market growth is sustained by:

  • Ongoing demand for PCR and rapid antigen tests

  • Expansion of government-led surveillance programs

  • Integration of diagnostics into primary care and telemedicine services

The market growth trajectory suggests a focus on innovation, improved test sensitivity, and diversified testing platforms rather than volume alone.

What Are the Key Growth Drivers?

  1. Rising Demand for Rapid and Accurate Testing

    • The need for timely COVID-19 diagnosis in hospitals, workplaces, and schools is critical.

    • Point-of-care (PoC) testing solutions enable on-site rapid results, increasing adoption.

  2. Government Screening Programs

    • National health authorities in Germany, France, and the UK fund mass testing and surveillance.

    • Policies supporting mandatory testing in high-risk environments drive continuous demand.

  3. Technological Advancements

    • RT-PCR assay kits and immunoassay test strips are increasingly sensitive and reliable.

    • Emerging multiplex testing platforms detect multiple variants simultaneously.

  4. Healthcare Infrastructure and Laboratory Expansion

    • Investment in diagnostic laboratories and mobile testing units enhances regional coverage.

    • Integration of digital reporting systems improves data management and public health response.

  5. Increased Awareness and Early Detection

    • Growing emphasis on early detection of asymptomatic cases encourages widespread testing.

What Challenges Are Restraining the Market?

  • Market Saturation – As COVID-19 cases decline in some regions, growth is limited.

  • Price Pressures – Competitive pricing of rapid antigen and antibody tests affects profitability.

  • Regulatory Hurdles – Approval processes for new diagnostics or variants can be lengthy.

  • Supply Chain Disruptions – Shortages of reagents and swabs impact production and distribution.

  • Variant Detection Complexity – Emergence of new SARS-CoV-2 variants necessitates updated diagnostic tools.

What Are the Emerging Trends Shaping the Industry?

  1. Point-of-Care (PoC) Testing Expansion – Home-based or community PoC tests are gaining traction.

  2. Multiplex Testing Platforms – Devices capable of detecting COVID-19 along with influenza or RSV.

  3. Digital Integration – AI and data analytics improve reporting, surveillance, and predictive modeling.

  4. Variant-Specific Diagnostics – Development of assays targeting Delta, Omicron, and future variants.

  5. Self-Testing and Consumer Adoption – At-home rapid antigen tests increase convenience and accessibility.

How Is the Market Segmented?

By Test Type

  • PCR Test – Gold standard for COVID-19 detection, widely used in hospitals and labs.

  • Antigen Test – Rapid detection, increasingly used for PoC and community testing.

  • Antibody Test – Used for seroprevalence studies and monitoring vaccine-induced immunity.

  • Others – Emerging methods including CRISPR-based and molecular point-of-care tests.

By Product

  • RT-PCR Assay Kits – Highly sensitive molecular diagnostics kits.

  • Immunoassay Test Strips – Rapid lateral flow and ELISA-based assays.

  • Others – Novel microfluidic devices and multiplex platforms.

By Sample Type

  • Nasopharyngeal Swab – Standard sample type for PCR and antigen testing.

  • Oropharyngeal (OP) Swab – Alternative swab for sensitive detection.

  • Nasal Swab – Less invasive, suitable for self-testing.

  • Blood Test – For antibody and immune response monitoring.

  • Others – Saliva and sputum-based tests for variant detection.

By Business Model

  • Point-of-Care (PoC) Testing – Rapid tests in clinics, pharmacies, workplaces, or at home.

  • Non-Point-of-Care Testing – Lab-based diagnostics with high sensitivity for hospitals and research centers.

By End Use

  • Hospitals – Primary users of PCR tests and high-sensitivity assays.

  • Diagnostic Centres and Clinics – Adopt rapid antigen and immunoassay testing for outpatient care.

  • Laboratories – Specialized labs conduct large-scale screening and variant surveillance.

  • Others – Airports, workplaces, schools, and research institutes.

Regional Insights Within Europe

United Kingdom

  • Government-funded mass testing programs, including NHS and workplace testing.

  • Strong adoption of PoC and lab-based PCR diagnostics.

Germany

  • Leading in laboratory infrastructure and public-private partnerships for diagnostic distribution.

  • Emphasis on high-throughput RT-PCR and antigen testing.

Italy

  • High hospital demand for PCR testing during seasonal infection peaks.

  • Government support for diagnostic labs in rural areas.

France

  • Integration of rapid testing in schools, workplaces, and community centers.

  • Investment in digital reporting systems for nationwide data collection.

Spain

  • Focus on PoC testing to support tourism and international travel.

  • Mobile testing units in urban and rural areas.

Other Countries

  • Nordic and Eastern European countries adopt a combination of lab-based and PoC tests.

  • Regional variations in government funding and reimbursement models impact adoption.

Competitive Landscape

Key Companies

  • Altona Diagnostics GmbH – PCR assay kits and molecular diagnostics innovation.

  • Genomica S.A.U – Specialized in RT-PCR solutions and high-throughput systems.

  • Clonit srl – Offers rapid antigen and antibody testing solutions.

  • BioMaxima SA – Supplies immunoassay strips and lab reagents.

  • Primerdesign Ltd – Advanced PCR test kits for hospital and lab applications.

Strategic Insights

  • Companies are focusing on multiplex and variant-specific diagnostic solutions.

  • M&A and collaborations enhance distribution capabilities across Europe.

  • Investment in AI-based platforms for faster result interpretation and reporting.

  • Expansion of PoC and at-home testing channels to capture consumer demand.

Regulatory Framework

  • European Medicines Agency (EMA) – Central authority for approval of in vitro diagnostics (IVDs).

  • National Health Authorities – Germany (BfArM), France (ANSM), UK (MHRA) regulate testing standards.

  • EU IVDR Compliance – Ensures safety, accuracy, and performance of diagnostic devices.

  • COVID-19 Specific Guidelines – Emergency use authorizations (EUA) expedited market entry.

Differences in regulatory frameworks across countries impact product launch timelines and market adoption strategies. Companies must navigate both EU-wide and local approvals to optimize distribution.

Future Outlook (2026–2035)

  • Revenue Growth – Expected to reach USD 17.78 Billion by 2035.

  • Innovation Focus – Multiplex assays, variant-specific tests, and digital integration.

  • Point-of-Care Expansion – Home-based testing and rapid results will drive adoption.

  • Government Programs – Ongoing surveillance and vaccination-linked testing will sustain demand.

  • Investment Opportunities – Stakeholders can focus on AI-enabled diagnostics, emerging swabless sampling methods, and portable PoC devices.

Actionable Insights for Investors:

  • Prioritize partnerships with labs and PoC testing providers.

  • Invest in companies developing variant-specific and multiplex diagnostic kits.

  • Monitor regional adoption trends, particularly in Germany, UK, France, and Italy.

  • Leverage digital reporting platforms for data-driven decision-making.

Browse More Reports

Healthcare Cloud Computing Market

Medical Spa Market

Assisted Reproductive Technology Market

Cannabis Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com